Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2626 to 2640 of 8915 results

  1. Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]

    Awaiting development Reference number: GID-TA11766 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

    Awaiting development Reference number: GID-TA10748 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]

    Awaiting development Reference number: GID-TA11699 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]

    Awaiting development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    Awaiting development Reference number: GID-TA11535 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285]

    Awaiting development Reference number: GID-TA11342 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Dupilumab for treating bullous pemphigoid [ID6479]

    Awaiting development Reference number: GID-TA11615 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Encorafenib with cetuximab and FOLFOX for untreated BRAF V600E mutation-positive metastatic colorectal cancer [ID6734]

    Awaiting development Reference number: GID-TA11961 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215]

    Awaiting development Reference number: GID-TA11199 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. VER-01 for treating chronic low back pain [ID6638]

    Awaiting development Reference number: GID-TA11842 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Nipocalimab for treating generalised myasthenia gravis [ID6562]

    Awaiting development Reference number: GID-TA11492 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]

    Awaiting development Reference number: GID-TA11759 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072]

    Awaiting development Reference number: GID-TA10960 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer [ID6317]

    In development Reference number: GID-TA11340 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Insulin efsitora alfa for treating type 2 diabetes [ID6499]

    In development Reference number: GID-TA11644 Expected publication date:  22 October 2026

    Technology appraisal guidance
    In development